JPMorgan Chase & Co. Begins Coverage on Kailera Therapeutics (NASDAQ:KLRA)

JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a report released on Tuesday, Marketbeat reports. The brokerage set an “overweight” rating and a $30.00 price target on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 42.11% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Evercore assumed coverage on Kailera Therapeutics in a report on Tuesday. They set an “outperform” rating on the stock. Leerink Partners started coverage on Kailera Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price objective for the company. Wall Street Zen upgraded shares of Kailera Therapeutics to a “hold” rating in a report on Saturday, April 25th. Jefferies Financial Group assumed coverage on shares of Kailera Therapeutics in a report on Tuesday. They issued a “buy” rating and a $48.00 target price on the stock. Finally, William Blair assumed coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Price Performance

NASDAQ KLRA opened at $21.11 on Tuesday. Kailera Therapeutics has a fifty-two week low of $20.86 and a fifty-two week high of $28.23.

Insider Buying and Selling at Kailera Therapeutics

In other Kailera Therapeutics news, Director Andrew T. Kaplan acquired 8,398,438 shares of Kailera Therapeutics stock in a transaction dated Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director directly owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This represents a 47.03% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Rtw Investments, Lp bought 500,000 shares of the firm’s stock in a transaction dated Monday, April 20th. The shares were acquired at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the transaction, the insider owned 10,776,820 shares of the company’s stock, valued at $172,429,120. This represents a 4.87% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 10,460,938 shares of company stock valued at $167,375,008.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.